hit counter

Methylphenidate Reduced Dishonesty and Cheating in 151 Adults; Atomoxetine Had No Effect

Editorial card showing methylphenidate molecular structure beside a die-rolling task, illustrating a counterintuitive randomized-trial result.

A 2026 double-blind randomized controlled trial by Kappes et al. in Psychopharmacology found something the smart-drug users likely wouldn’t have predicted: a single 30 mg dose of methylphenidate reduced dishonest misreporting on a die-rolling task from ~22% of trials in the placebo arm to ~6% (in the methylphenidate arm).1 Atomoxetine, a noradrenergic comparator, had no …

Read more

tVNS Alters Effort and Reward Decisions in Severe Depression

Photoreal illustration of an ear-clip vagus nerve stimulation electrode, with neural pathway motifs representing reward-effort circuits.

An ear-clip that modulates mood by stimulating the vagus nerve has obvious appeal — but the evidence base for non-invasive tVNS in depression has been mixed for a decade. A 2026 cross-over RCT by Forbes et al. sharpens what specifically tVNS does well.1 Research Highlights Transcutaneous vagus nerve stimulation (tVNS) is a non-invasive ear-electrode version …

Read more

Naltrexone/Bupropion Reduced Food Intake in Binge-Eating Lab Study

Photoreal illustration of brain reward circuitry overlaid on imagery of palatable food, conveying pharmacological reduction of consummatory reward.

Lisdexamfetamine remains the only FDA-approved medication for binge-eating disorder — a serious condition affecting roughly 1.2% of adults. A 2026 human laboratory study by McKee and colleagues tests whether naltrexone/bupropion, already approved for obesity, reduces the food-reward mechanisms that drive binge episodes.1 Research Highlights Binge-eating disorder (BED) is the most common eating disorder in the …

Read more

Striatal Dopamine Drops From Psychosis to Schizophrenia Remission

Photoreal illustration of a brain with the striatum highlighted and dopamine synthesis pathways visualized, representing longitudinal PET imaging in schizophrenia.

The dopamine hypothesis of schizophrenia is the field’s longest-running mechanistic story, and most of its supporting evidence has been cross-sectional. A 2026 longitudinal PET study by Schulz and colleagues followed the same 28 patients across psychosis and early remission.1 Research Highlights The dopamine hypothesis of schizophrenia is the field’s longest-running mechanistic story. Cross-sectional 18F-DOPA PET …

Read more

BDNF Gene Transfection & Pramiprexole Combo Effectively Treat Parkinson’s Disease in Rat Models (2024 Study)

Parkinson’s disease (PD), a degenerative disorder that predominantly affects the motor system, has long been a challenging condition to manage due to its complex pathology and the limited efficacy of available treatments. However, recent research presents a beacon of hope through a novel combined therapy targeting the core of Parkinson’s disease’s neuronal degradation. This innovative …

Read more

Internet Addiction Linked to 5-HT2A Receptor Polymorphism: Serotonin HTR2A Gene rs6313 (2024 Study)

In the digital age, Internet Addiction Disorder (IAD) emerges as a complex interplay of technology, psychology, and genetics. This intricate relationship underscores the need for a multidisciplinary approach to understanding and addressing IAD. A recent study analyzed the genetic underpinnings of internet addiction and discovered a strong link with the serotonin 2A receptor gene (HTR2A) …

Read more

Oxycodone vs. Other Opioids: Distinct Epigenetic Effects & Molecular Adaptations (2023 Review)

The opioid crisis, particularly in North America, has spotlighted oxycodone as a central figure due to its significant role in addiction and overdose deaths. A recent review analyzed the genomic and epigenetic mechanisms behind oxycodone’s effects compared to other opioids, shedding light on its unique impact on addiction pathways. Highlights: Oxycodone, a semi-synthetic opioid derived …

Read more